Fortive (FTV -2.32%), an industrial technology group with a focus on productivity and healthcare solutions, reported its Q2 2025 earnings on July 30, 2025. The most notable news in the release was the completion of its Ralliant (Precision Technologies) spin-off, alongside results showing stable GAAP revenues and earnings, but with modest declines from the prior year. Fortive reported GAAP revenue from continuing operations of $1,020 million, slightly ahead of the analyst estimate of $1,013.4 million in Q2 2025. Adjusted diluted earnings per share (EPS) from continuing operations reached $0.58 (non-GAAP), narrowly missing the consensus estimate of $0.59 in Q2 2025. Overall, the quarter featured stable margins and cash flow, but slower top-line momentum and a focus on post-spin strategic execution.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS – Diluted (Non-GAAP) | $0.58 | $0.59 | $0.56 | 3.6% |
| Revenue | $1,016 million | $1,013.4 million | $1,020 million | (0.4 %) |
| Adjusted EBITDA (Non-GAAP) | $288 million | $291 million | (1.0 %) | |
| Free Cash Flow (Non-GAAP) | $180 million | $198 million | (9.1 %) | |
| Revenue – Intelligent Operating Solutions | $697 million | $697 million | 0.0% |
Source: Analyst estimates for the quarter provided by FactSet.
Fortive (FTV -2.32%) builds and sells technology-based products and software for industrial, safety, and healthcare markets. The business operates through two main segments: Intelligent Operating Solutions and Advanced Healthcare Solutions.
In recent years, Fortive has sharpened its strategy by spinning off businesses, including the recent Ralliant separation. Its key to success lies in bringing recurring, high-value products and services to market, prioritizing operational discipline, and taking advantage of its Fortive Business System—Fortive's approach to continuous process improvement and cost control.
The past quarter was pivotal for Fortive due to the completed Ralliant spin-off on June 28, 2025. This allowed Fortive to concentrate on its Intelligent Operating Solutions and Advanced Healthcare Solutions segments. Revenue from continuing operations (GAAP) edged past market estimates, but fell slightly compared to the previous year, reflecting a 0.4% decline in Q2 2025. Core revenue, which strips out the effects of acquisitions, divestitures, and currency changes, dipped 0.7% (non-GAAP) in Q2 2025. This marks a slowdown from the prior year’s core revenue growth of 3.9% (non-GAAP) in Q2 2024—a notable trend for both segments.
Profitability metrics held mostly steady. Adjusted EBITDA was $288 million in Q2 2025, a decrease of 1.0% from the comparable period in 2024. Margins remained comparable, with the adjusted EBITDA margin (non-GAAP) at 28.4% in Q2 2025, down 20 basis points. Net income on a GAAP basis stayed flat year over year at $112 million in Q2 2025. Free cash flow (non-GAAP) from continuing operations was $180 million in Q2 2025, down 9.1% from last year The trailing twelve-month free cash flow (non-GAAP) increased to $939 million, a 13.7% improvement for the period ended in Q2 2025.
Within the Intelligent Operating Solutions segment, revenue was essentially flat compared to last year. Adjusted EBITDA margin for this group improved by 50 basis points in Q2 2025, suggesting success in operational performance, even as reported GAAP operating margin and profit eased slightly. In Advanced Healthcare Solutions, revenue declined 1.3% in Q2 2025, while core revenue was down 1.9%. Margins in this segment improved modestly at both the operating profit (GAAP) and adjusted EBITDA (non-GAAP) lines, even as sales softened in Q2 2025. Segment-level results demonstrate ongoing cost discipline but reveal pressure on organic (non-GAAP) growth in Q2 2025.
No major product launches or customer wins were highlighted during the quarter. Management acknowledged “uncertainty related to trade, healthcare, and government spending policy impacting demand.” The Fortive Business System—a company-wide methodology for operational improvement and efficiency—continued to underpin profit performance, helping the business maintain stability during a period of slower sales growth. Fortive completed $345 million in share repurchases in the first half of 2025, returning capital to shareholders. Its cash and equivalents balance (GAAP) increased significantly to $1,832.7 million as of June 27, 2025. The company declared a dividend of $54.2 million (GAAP) for the six months ended June 27, 2025.
Fortive has set its full-year 2025 adjusted diluted EPS target in the range of $2.50 to $2.60 for continuing operations. The company did not provide revenue or segment-level outlooks for the remainder of the year. Management reiterated belief in its medium-term financial framework, noting that it “remains firmly intact.” but did not signal any imminent improvement in growth trends.
Investors and industry watchers should keep an eye on Fortive’s ability to reignite organic revenue growth as it moves forward in its post-spin configuration. Oversight will likely focus on supply chain resilience, regulatory risks in healthcare, and the company’s ability to drive innovation and win new business in both its core segments. Fortive pays a dividend of $54.2 million for Q2 2025.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.